Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Novo Nordisk and Glooko Partner to Improve Diabetes Management


Blood Glucose

The pharmaceutical company will apply Glooko’s FDA-cleared, HIPPA-compliant platform to develop an app designed to help diabetic patients improve their blood glucose control.

Share this!

January 10, 2017 | by Sarah Hand, M.Sc.

Danish diabetes drugmaker, Novo Nordisk, has partnered with mHealth company, Glooko, to develop patient-centric apps for better diabetes management. The pharmaceutical company will apply Glooko’s FDA-cleared, HIPPA-compliant platform to develop an app designed to help diabetic patients improve their blood glucose control.

Novo Nordisk is the world’s leading supplier of diabetes medications. The partnership will provide California-based Glooko with access to Novo Nordisk’s customer information, along with its diabetes-based educational resources.

“We will add that [content] to our mobile platform,” Glooko CEO Rick Altinger told MedCity News. “The vision is to leverage data to drive better and faster decisions to help patients and their caregivers get to better outcomes.”

Glooko’s diabetes management platform has allowed the company to collect patient data on about one million diabetic patients globally. In addition, over 4,800 health systems have adopted the technology for disease management and remote patient monitoring.

According to Altinger, Glooko not only helps patients track all of the variables that affect their diabetes management, but it also offers companies a way to add diabetes information into electronic health records (EHR). “Diabetes is a data-driven disease, said Altinger. “Health systems can pull in data from Glooko, into workflows and integrate with EHRs if they want.”

Aside from this most recent deal with Novo Nordisk, Glooko has already established deals with diabetes medical device makers, including Roche. As the agreement with Novo Nordisk is nonexclusive, the company’s partnership with IBM Watson Health will likely also come into play.

“We are excited to partner with Glooko and to take another step towards delivering digital health offerings that help people with diabetes to improve their blood glucose control,” said Christian Kanstrup, Novo Nordisk’s senior vice president for strategy, access and marketing. “Working in partnerships will furthermore enhance our ability to demonstrate the real-world value of our portfolio of diabetes treatments.”

While it’s unclear exactly what products will come out of the partnership, Glooko has said that personalized support for diabetic patients and their caregivers is the major goal. The first digital health offering could be made available before the end of this year.

Keywords: Diabetes, mHealth, Disease Management


Share this with your colleagues!

Gilead’s Newest Hepatitis C Drug Gets FDA Approval

July 21, 2017 - Dominant player in the chronic hepatitis C virus (HCV) market Gilead has received US Food and Drug Administration (FDA) approval for its newest treatment, Vosevi.

Featured In: Pharmaceutical News

Detecting Alzheimer’s Biomarkers in the Blood Could Improve Early Diagnosis

July 20, 2017 - In an effort to improve rates of early diagnosis and intervention, researchers at Washington University in St. Louis have developed a blood test that can detect some of the hallmarks of Alzheimer’s disease.

Featured In: Biotech News

Insurance Coverage Under the Affordable Care Act Supports Clinical Trial Enrollment, Says Study

July 20, 2017 - Since the Patient Protection and Affordable Care Act (ACA) was passed in 2010, insurance approval for patients wishing to participate in oncology clinical trials has increased, according to a recent study published in the journal, Clinical Cancer Research.

Featured In: Clinical Trial News


Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know


Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned

EDC and eSource: Combined for Better Data and Faster Insights

Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide

How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology

Copyright © 2016-2017 Honeycomb Worldwide Inc.